Literature DB >> 22964779

Antiaging effects of simvastatin on vascular endothelial cells.

Junping Lei1, Xiaosong Gu, Zhong Ye, Jianbo Shi, Xing Zheng.   

Abstract

The anti-inflammatory, antioxidative, and antiarteriosclerosis activities of simvastatin along with its protective effects on the endothelium suggest that it may also have antiaging effects. The aim of this study was to investigate the antiaging effects of simvastatin as well as its effects on sirtuin 1 (SIRT1) expression in endothelial cells. Aged rats and human umbilical vein endothelial cells were treated with simvastatin in the presence and absence of oxidized low-density lipoprotein (OX-LDL). Aortic β-galactosidase staining was undertaken to determine senescence, and SIRT1 protein expression was evaluated using Western blot analysis. After simvastatin therapy, arterial endothelial cell aging was significantly reduced, and SIRT1 expression was significantly increased. The OX-LDL significantly accelerated the senescence of umbilical vein endothelial cells and decreased SIRT1 expression. The OX-LDL-induced downregulation of SIRT1 was blocked by simvastatin. Simvastatin treatment also reduced umbilical vein endothelial cell aging and increased SIRT1 expression.

Entities:  

Keywords:  OX-LDL; SIRT1; antiaging; simvastatin; vascular endothelial cells

Mesh:

Substances:

Year:  2012        PMID: 22964779     DOI: 10.1177/1076029612458967

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  6 in total

Review 1.  Regulatory Effects of Statins on SIRT1 and Other Sirtuins in Cardiovascular Diseases.

Authors:  Danial Khayatan; Seyed Mehrad Razavi; Zahra Najafi Arab; Maryam Khanahmadi; Saeideh Momtaz; Alexandra E Butler; Fabrizio Montecucco; Yuliya V Markina; Amir Hossein Abdolghaffari; Amirhossein Sahebkar
Journal:  Life (Basel)       Date:  2022-05-20

2.  Fibroblast growth factor 21 delayed endothelial replicative senescence and protected cells from H2O2-induced premature senescence through SIRT1.

Authors:  Jinhua Yan; Jinli Wang; Huijin Huang; Yi Huang; Tao Mi; Cuntai Zhang; Le Zhang
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

Review 3.  Regulation of SIRT1 by oxidative stress-responsive miRNAs and a systematic approach to identify its role in the endothelium.

Authors:  Zhen Chen; Tzu-Pin Shentu; Liang Wen; David A Johnson; John Y-J Shyy
Journal:  Antioxid Redox Signal       Date:  2013-04-25       Impact factor: 8.401

4.  Combination therapy of lovastatin and AMP-activated protein kinase activator improves mitochondrial and peroxisomal functions and clinical disease in experimental autoimmune encephalomyelitis model.

Authors:  Inderjit Singh; Devadoss J Samuvel; Seungho Choi; Nishant Saxena; Avtar K Singh; Jeseong Won
Journal:  Immunology       Date:  2018-02-08       Impact factor: 7.397

5.  Preclinical Activity of Simvastatin Induces Cell Cycle Arrest in G1 via Blockade of Cyclin D-Cdk4 Expression in Non-Small Cell Lung Cancer (NSCLC).

Authors:  Yu-Wei Liang; Chi-Chang Chang; Chao-Ming Hung; Tzu-Yu Chen; Tzuu-Yuan Huang; Yi-Chiang Hsu
Journal:  Int J Mol Sci       Date:  2013-03-12       Impact factor: 5.923

6.  Metformin regulates oxLDL-facilitated endothelial dysfunction by modulation of SIRT1 through repressing LOX-1-modulated oxidative signaling.

Authors:  Ching-Hsia Hung; Shih-Hung Chan; Pei-Ming Chu; Huei-Chen Lin; Kun-Ling Tsai
Journal:  Oncotarget       Date:  2016-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.